Moderna, Inc. (MRNA) earnings on July 31, 2026

What the stock did

High
+4.2%
Low
-8.9%
Close
-5.3%

Moderna's vaccine candidate failed a key test in late-stage trials, causing the stock to drop sharply. The price fell as much as 8.8% and closed down 3.4%.

How the outlook turned out

Outlook
Pessimistic · Accurate

How each outlook is classified

Written and reviewed by Volatly, the company that organizes the context around corporate events and leaves its archive open to review afterwards.

Who is behind Volatly How each outlook is measured

Notice. This is an archive of already closed events, not financial advice. There is no personalised recommendation here: nobody has asked about your situation or your goals. Volatly organizes the context and publishes its archive with the hits and the misses; the decision and the risk belong to whoever invests.